Atea Pharmaceuticals Inc

NASDAQ:AVIR   4:00:00 PM EDT
4.69
+0.11 (+2.40%)
4:03:40 PM EDT: $4.69 0.00 (0.00%)
Products

Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted To AT-752 For Treatment Of Dengue

Published: 09/26/2022 11:10 GMT
Atea Pharmaceuticals Inc (AVIR) - Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to At-752 for Treatment of Dengue.
Atea Pharmaceuticals Inc - At-752 is a Novel, Orally Administered, Direct-acting Antiviral in Phase 2 Development for Treatment of Dengue.
Atea - At-752 is Showing Potent in Vitro and in Vivo Activity in Preclinical Studies and Favorable Safety and Tolerability in Phase 1 Trial.